Dendritic Cells in Human Atherosclerosis: From Circulation to Atherosclerotic Plaques by Van Vré, Emily A. et al.
Hindawi Publishing Corporation
Mediators of Inﬂammation
Volume 2011, Article ID 941396, 13 pages
doi:10.1155/2011/941396
Review Article
DendriticCells in Human Atherosclerosis: From Circulation
to Atherosclerotic Plaques
EmilyA.Van Vr´ e,1 Ilse Van Brussel,1 Johan M. Bosmans,1
ChristiaanJ. Vrints,1 and Hidde Bult2
1Division of Cardiology, Department of Translational Pathophysiological Research, Faculty of Medicine, University of Antwerp,
2610 Wilrijk, Belgium
2Division of Pharmacology, Department of Translational Pathophysiological Research, Faculty of Medicine,
University of Antwerp, 2610 Wilrijk, Belgium
Correspondence should be addressed to Hidde Bult, hidde.bult@ua.ac.be
Received 11 May 2011; Accepted 31 July 2011
Academic Editor: Freek Zijlstra
Copyright © 2011 Emily A. Van Vr´ e et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Background. Atherosclerosis is a chronic inﬂammatory disease with atherosclerotic plaques containing inﬂammatory inﬁltrates
predominantly consisting of monocytes/macrophages and activated T cells. More recent is the implication of dendritic cells (DCs)
in the disease. Since DCs were demonstrated in human arteries in 1995, numerous studies in humans suggest a role for these
professional antigen-presenting cells in atherosclerosis. Aim. This paper focuses on the observations made in blood and arteries
of patients with atherosclerosis. In principal, ﬂow cytometric analyses show that circulating myeloid (m) and plasmacytoid (p)
DCs are diminished in coronary artery disease, while immunohistochemical studies describe increased intimal DC counts with
evolving plaque stages. Moreover, mDCs and pDCs appear to behave diﬀerently in atherosclerosis. Yet, the origin of plaque DCs
and their relationship with blood DCs are unknown. Therefore, several explanations for the observed changes are postulated.
In addition, the technical challenges and discrepancies in the research ﬁeld are discussed. Future. Future studies in humans, in
combinationwithexperimentalanimalstudieswillunravelmechanismsleadingtoalteredbloodandplaqueDCsinatherosclerosis.
As DCs are crucial for inducing but also dampening immune responses, understanding their life cycle, traﬃcking and function in
atherosclerosis will determine potential use of DCs in antiatherogenic therapies.
1.Introduction
Atherosclerosis takes a huge toll on our society. It is the lead-
ing cause of morbidity and mortality in the Western world,
and growing incidence of atherosclerosis-related diseases has
also been recently observed in developing countries [1]. It
has become evident that inﬂammation mediated both by
innate and adaptive immunity plays an important role even
in the earliest stages of the development of atherosclerotic
lesions [2, 3].
Dendritic cells (DCs) constitute a family of professional
antigen-presenting cells that have the unique ability to
induce primary T-cell responses. Moreover, they are not only
essential in launching immune reactions against harmful
antigens, but also in maintaining immune tolerance [4, 5].
As key modulators of immune responses, they are likely to
play a crucial role in directing innate or adaptive immunity
against altered self-antigens present in atherosclerosis, such
as oxidized epitopes on apoptotic cells, oxidized low-density
lipoproteins (oxLDL), or heat shock proteins (Hsp) [6].
As illustrated in Figure 1, the general concept on the
life cycle of DCs involves three stages. They originate
from haematopoietic stem cells in the bone marrow and
circulate as precursors in the blood stream, taking residence
in target tissues at sites of potential antigen entry. Within
these tissues, they give rise to immature interstitial DCs
that act as sentinels, which continuously and eﬃciently
sample the antigenic content of their microenvironment.
In the steady state, immature DCs capture harmless self-
antigens in the absence of inﬂammatory signals. They might2 Mediators of Inﬂammation
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Figure 1: Schematic presentation of life cycle of DCs.
enter the regional lymph nodes to present the self-antigen
to na¨ ıve or resting T cells, which will be deleted by the
induction of apoptosis, silenced by the induction of anergy
or primed to become regulatory T cells [4]. In contrast,
when infection and tissue damage occurs, immature DCs
take up antigens in the presence of inﬂammatory signals,
which cause activation and functional transformation into
mature DCs, thereby downregulating endocytotic capac-
ity and upregulating chemokine receptors (e.g., CCR-7),
adhesion (e.g., CD50) and activation molecules needed for
antigen presentation (e.g., CD83, CD86) [4, 5]. Meanwhile
they exit the nonlymphoid tissues to migrate via aﬀerent
lymph to lymphoid tissues (lymph nodes or spleen), where
they complete maturation. Mature DCs will present short
peptide fragments, which are bound to the surface molecules
CD1 or major histocompatibility complex- (MHC-) I or
MHC-II. Consequently, they will activate (na¨ ıve) T and B
lymphocytes that recognize the presented antigen [5, 7–9].
The present review is aimed at summarizing current
knowledge of the role of DCs in the pathogenesis of human
atherosclerosis: from circulating DC precursors in patients
with coronary artery disease (CAD) to DCs found in
humanatheroscleroticlesions.Technicalchallengesandopen
questions in this research ﬁeld are discussed in detail.
2.CirculatingDCs inCAD
2.1. Subtypes of Blood DC Precursors. Two main DC pre-
cursor subtypes can be identiﬁed in human blood: myeloid
(m)DCs and plasmacytoid (p)DCs. As DC precursors they
are relatively immature and express only low levels of
adhesion and costimulatory molecules—at least in physio-
logicalconditions[10–12].mDCs(0.26%amongleukocytes)
descend from the myeloid lineage, and express blood DC
antigen (BDCA)-1 (= CD1c), CD11c, and Toll-like receptors
TLR2, TLR4, TLR5, and TLR3 [13–15]. They secrete mainly
IL-12 in response to bacterial components such as peptido-
glycans, lipopolysaccharide (LPS) or ﬂagellin, and extracel-
lular bacterial DNA, respectively. Unlike mDCs, pDCs (0.2%
among leukocytes) express BDCA-2 (= CD303) and CD123,
and are specialized in innate antiviral immune responses
by producing copious amounts of type I interferons upon
exposure of intracellular TLR9 and TLR7 to DNA and RNA
viruses, respectively [16–18]. Apart from responding to dif-
ferent pathogen-associated molecular patterns (PAMPs) and
secreting diﬀerent cytokines, mDCs and pDCs also diﬀer
in migration behaviour [16, 17, 19–22]. Generally it is as-
sumed that mDCs are the conventional DCs that inﬁltrate
peripheral tissues while pDCs migrate directly from the
blood into lymphoid organs.
Finally, a small (0.02% of leukocytes) third population of
blood DCs expressing CD11c, and BDCA-3 (= CD141) but
not BDCA-1, CD123 and BDCA-2 can be distinguished [23].
BDCA-3+ mDCsarefarlessstudiedthantheclassicalBDCA-
1+ mDCs, but recent reports stress their unique function and
importance. They emerge as a distinctive myeloid DC subset
that is characterized by high expression of TLR3, production
of IL-12 and IFN-β, and a superior capacity to induce
T helper-1 cell responses, when compared with BDCA-
1+ mDCs [24]. Moreover, BDCA-3+ mDCs are endowed
with the capacity to cross-present necrotic cell antigens and
induce cytotoxic T-cell responses [24].
2.2. Decline of Blood DCs in CAD. In 2006 we reported for
theﬁrsttimeadecreaseincirculatingDCprecursors(BDCA-
1+ mDCs, BDCA-2+ pDCs) in patients with coronary artery
disease (CAD), the clinical manifestation of atherosclerosis
[25]. CAD was determined by angiography and deﬁned as
more than 50% stenosis in one or more coronary arteries.
Blood DCs were enumerated by multicolour ﬂow cytometry.
Absolute and relative numbers of circulating BDCA-2+
pDCs were signiﬁcantly lower (55% decline) in 18 CAD
patients, compared to 18 age- and sex-matched healthy
volunteers. Absolute BDCA-1+ mDC numbers tended to be
smaller in patients, while relative numbers were signiﬁcantly
diminished (21% decline). Simultaneously and indepen-
dently, Yilmaz et al. [26] also found a marked reduction
in mDC precursors in CAD patients, though the decline
in pDCs was less pronounced. These minor diﬀerences
between both early reports may be due to insuﬃcient power
of those studies. In addition, Yilmaz et al. showed that
patients with acute myocardial infarction (AMI), which were
excluded by van Vr´ e et al. [25], had the most dramatic
decline (63%) in blood mDCs [26]. However, this may beMediators of Inﬂammation 3
in response to development of myocardial necrosis rather
than atherosclerosis in se. Moreover, it may be due to the
doubling of the total leukocyte count after AMI, resulting
in lower relative numbers of mDCs in patients with AMI,
but comparable absolute counts between AMI patients and
patients with stable CAD. This illustrates an important tech-
nical weakness of ﬂow cytometric enumeration and stresses
the importance of fairly stable unaltered total leukocyte
counts, as ﬂow cytometry determines the relative fraction
of DCs within the total leukocyte population. Otherwise
it would be preferable to add ﬂuorescent beads as internal
standards to the blood sample, which allows for absolute cell
counting.
Subsequently,weinvestigatedwhetherthedeclineofblood
DCs in CAD patients was related to the number of diseased
vessels (one- versus three-vessel disease) or type (stable ver-
sus unstable angina pectoris) of CAD [27]. This study also
determined total blood DCs, identiﬁed as lineage (CD3,
CD14, CD16, CD19, CD20, CD56) negative and HLA-
DR positive. Again relative and absolute numbers of pDCs
and mDCs were signiﬁcantly lower (35 and 34%, resp.)
in patients with coronary atherosclerosis. Interestingly, the
overall lineage− HLA-DR+ blood DCs, which also include
other blood DCs (e.g., BDCA-3+) or more mature blood
DCs, conﬁrmed the decline of BDCA+ DC precursors. How-
ever, the counts of circulating DCs dropped to the same
extent in three groups of CAD patients, irrespective of
the number (one or three) of aﬀected arteries or the type
(stable or unstable) of angina. In analogy, Yilmaz et al.
found no diﬀerences between clinically stable or unstable
CAD [26]. Yet, in a subsequent more extended study [28]
with a cohort of 290 patients, they found that the numbers
of pDCs, mDCs, and total DCs declined as the extent of
coronary atherosclerosis increased. In that study they exa-
mined patients with suspected stable CAD, but used a more
reﬁned “CAD score.” They assessed the maximum grade of
stenosis in 15 well-deﬁned segments of the three coronary
arteries and their main side branches. These values were
c o u n t e du pt oo b t a i na no v e r a l lC A Ds c o r e ,a n dt h e n
patients were subdivided into 4 groups: CAD excluded, early
CAD, moderate CAD, and advanced CAD. Moreover, they
showed that the decrease in DC numbers was an indepen-
dent predictor of the presence of CAD when several risk
factors (age, male gender, diabetes, and hypertension) were
included [28].
Surprisingly, Shi et al. [29] using CD11c and CD123
ratherthanBDCA-1andBDCA-2asbloodDCmarkers,des-
cribed increased CD11c+ and unchanged CD123+ DC num-
bersinmenwithstableCAD.Yet,recentlyweunderlinedthat
circulating DCs decline in CAD, irrespective of the subset
marker (BDCA-1 or CD11c for mDCs, BDCA-2 or CD123
for pDCs) that was used for enumeration [30]. No details on
timing of blood sampling are mentioned by Shi et al. It may
be that in the CAD patients blood samples were taken imme-
diately after a percutaneous coronary intervention (PCI).
Since we noticed that PCI resulted in decreased leukocyte
numbers shortly after the intervention (unpublished data,
Van Vr´ e et al.), this may have invoked a rise of the rel-
ative proportions of DC counts. Therefore, with respect
to standardisation and to minimize interfering factors, blood
sampling before the intervention seems preferable.
2.3.PossibleExplanationsfortheDeclineofBloodDCsinCAD.
At the moment the mechanisms responsible for the decline
of blood DCs in atherosclerosis are still unclear. Diﬀerent
possibilitiesarediscussedbelowandsummarizedinFigure2.
2.3.1.ImpairedDiﬀerentiationfromBoneMarrowProgenitors.
Decreased production or release from the bone marrow
could result in reduced blood DC precursor numbers. As
discussed above, DCs are also necessary for induction of
tolerance against harmless antigens [5, 31]. Consequently, a
diminution in DC precursors could promote the develop-
ment of (auto)immune disease, such as atherosclerosis [32].
Interestingly, we recently showed diminished plasma Flt3
ligand (Flt3L) concentrations in CAD [12]. Flt3L is a major
cytokine involved in both pDC and mDC development from
haematopoietic stem cells and their release from the bone
marrow [33–35]. As plasma Flt3L correlated with blood DC
counts, the reduced blood DCs in CAD might be caused by
impaired DC diﬀerentiation from bone marrow progenitors.
Until now, it remains unclear why plasma Flt3L levels are
lowered in CAD. In contrast, plasma concentrations of the
DC growth factor GM-CSF were similar in CAD patients
and controls and did not correlate with mDC or pDC counts
[12], indicating that it is unlikely that GM-CSF accounts for
the decreased numbers of blood DCs in human CAD.
2.3.2. Increased DC Turnover. Another explanation for the
decreased DC numbers could be the result of increased
turnover, that is, decreased survival or production versus
apoptosis rates. Atherosclerosis is a chronic disease, evolving
over several decades with inﬂammatory reactions taking
place from the earlier stages. It is plausible that in the end
as symptoms emerge and the exposure to (new) antigens—
derived from stressed and dying cells, lipid, or protein mod-
iﬁcations due to oxidative stress in the plaque—increases,
the immune system’s “reserve pool” has become exhausted.
For instance it was demonstrated that oxidized low-density
lipoprotein, one of the main antigens present in plaques
and in the circulation of atherosclerotic patients, may cause
increasedapoptosisofDCs[36].Interestingly,nodeclinewas
observed [25–27] for other blood cells, such as monocytes,
pointing to a speciﬁc role of DCs in atherogenesis. As DCs
form the major patrol system of the body, involved in ﬁrst-
line defence, innate and adaptive immunity, they may be the
most sensitive/vulnerable to local and systemic changes, or
neoepitopes, presented during atherosclerosis. In the end,
this may result in a system that is no longer able to sustain
the number of blood DCs. Indeed, numbers of circulating
blood DCs, in particular pDCs, decline with increasing age
(unpublished data, Van Vr´ ee ta l . ) .H o w e v e r ,w h e na g ew a s
includedascovariate,thedeclineofmDCsandpDCsinCAD
patients appeared to be independent of the eﬀect of age [27].
2.3.3. DC Activation Leading to Loss of Subset Markers.
Activation of blood DCs by factors in the circulation (e.g.,4 Mediators of Inﬂammation
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Figure 2: Possible mechanisms responsible for the decline of blood DCs in atherosclerosis.
oxLDL) could account for diminished blood DC numbers
by reducing the expression of precursor markers. Indeed, it
has been described that pDC maturation results in complete
BDCA-2 downregulation [23, 30, 37], and this could poten-
tially lead to underestimation of circulating pDC numbers.
In addition, we recently showed that ex vivo DC activation
resulted in an increase in CD11c on mDCs and CD123 on
pDCs [30]. Thus, when diﬀerent DC numbers are found
between study populations, the DC activation status needs
to be veriﬁed, since the numerical changes may result from
thealteredexpressionofthesubsetmarkersduringactivation
[30]. Yet, by using CD11c/BDCA-1 and CD123/BDCA-2
ratios to assess DC activation, no diﬀerences were found
between controls and CAD patients [30]. From this it was
concluded that there was no indication for overt activation
of DC precursors in patients with CAD.
2.3.4. DC Activation Leading to Increased Extravasation.
Though several studies investigated numbers of subsets of
DCs in the circulation of CAD patients, very little additional
information is available on the status of maturation and acti-
vation in circulating DCs. It is possible that in inﬂammatory
conditions systemic activation occurs in the blood and this
could lead to increased extravasation or apoptosis of blood
DCs. Interestingly, inverse associations of circulating mDCs,
pDCs (and total DCs) were found with blood markers of
inﬂammation: CRP and IL-6 [25–28]. Upon stimulation by
circulating oxLDL or other atherosclerosis-related modiﬁed
proteins, blood DCs may become activated, upregulate
chemokine receptors such as CCR-7, and then travel towards
lymphoid organs or inﬂamed tissues, such as atherosclerotic
plaques.
Yilmaz et al. assessed the activation status of blood DC
precursors and reported a weak expression of costimulatory
molecules CD40 and CD86 on circulating BDCA-1+ mDCs
or BDCA-2+ pDCs [26], without diﬀerences between control
and CAD patients. We also detected very few activated blood
DCs: a minority of circulating mDCs (14–22%) and pDCs
(14–20%) had a more mature phenotype and expressed but
lowlevels(MFI)ofCD83,CD86,and/orCCR7.Nevertheless,
weshowedthatthefrequencyofCD86andCCR-7expressing
mDCs was less in CAD patients whereas this was not seen in
pDCs [12]. This could point to increased eﬄux or apoptosis
of activated blood CD86+CCR-7+ mDCs, contributing to
their decline in blood.
2.3.5. Functional Capability of Circulating DC Precursors in
CAD. As blood DC precursors from CAD patients remainedMediators of Inﬂammation 5
fairly immature, we investigated their capability to achieve
maturation. Therefore, we incubated whole blood samples
with TLR ligands ex vivo, and then evaluated expression of
activation markers by means of ﬂow cytometry. Stimulation
with the TLR-4 ligand LPS upregulated the expression
of CD83 and CD86 on mDCs, without changing CCR-7
expression or IL-12 secretion. Moreover, there were no dif-
ferences between mDCs from CAD patients or controls. For
pDCs, patients showed a weaker upregulation of CD83 and
less IFN-alpha secretion upon stimulation with imiquimod,
a TLR7 ligand. Hence, these results indicate that although
mDCs decline in CAD patients, they appear to be function-
ing in a normal way. In contrast, pDCs from CAD patients
are not only reduced in numbers, but also seem subactive
[12].
Finally, as monocytes can serve as precursors for DCs
in peripheral tissues [38], three groups used a completely
diﬀerent approach and studied the function of monocyte-
derived (mo)DCs in CAD. They isolated peripheral blood
monocytes from CAD patients and diﬀerentiated them ex
vivo for several days with GM-CSF and IL-4. moDCs from
patients with coronary syndromes, particularly unstable
angina, appeared to be more activated compared to moDCs
from controls or healthy volunteers [39–41]. These data
suggest that monocytes from CAD patients when exposed
to DC growth factors in atherosclerotic lesions will be more
prone to diﬀerentiate into activated DCs.
2.3.6. Drug-Induced Changes in Blood DCs. Cardiovascular
disease-related medication, taken by CAD patients, might
inﬂuence numbers, phenotype, or function of blood DCs
in atherosclerosis. Indeed, several in vitro studies show
potential eﬀects of cardiovascular drugs on DC maturation
and function.
Aspirin promotes early moDC diﬀerentiation to func-
tionally active, immature DCs, and strongly maintains these
cells in an immature state [42–44]. In vivo experiments in
mice demonstrated an impairment of cell-mediated immune
responses, which was not due to the inability of aspirin-
treated DCs to migrate to drained lymphoid tissue [42]. In
contrast to immature DCs, fully diﬀerentiated DCs were not
susceptible to inhibition by aspirin [43]. The latter indicates
that it is the process of diﬀerentiation, rather than the fun-
ction of mature DCs, which is the target of aspirin.
Koﬂer et al. demonstrated that statins inhibited adhesion
and transmigration of moDCs through dysfunctional endo-
thelial cells in vitro [45], suggesting that under statin
treatment less DCs would accumulate in atherosclerotic
plaques. Although statins have been reported to suppress DC
maturation and function, [46–48], data on in vitro DC acti-
vation in the presence of statins remain rather conﬂicting. It
seems that statins partially suppress in vitro DC maturation
by inhibition of the NFκBa c t i v i t y[ 48], but may aﬀect DC
function diﬀerently [46] depending on the maturation para-
meters analysed and the type of statin tested.
Studies on the eﬀects of beta blockers on DC maturation
and function are absent, though beta blockers may reverse
changes in leukocyte distribution. Von Haehling et al.
demonstrated that the decrease in lymphocytes and the
in-crease in neutrophils in patients with chronic heart
failure are less pronounced when patients are on a beta-
blocker therapy [49]. After distal type acute aortic dissection,
early use of beta blockers prevented excessive inﬂammation,
indicated by lower maximum white blood cell counts
and lower serum CRP levels. This suggests pleiotropic
eﬀects of beta blockers on the inﬂammatory response
[50].
Also angiotensin-converting enzyme- (ACE-) inhibitors
and calcium entry blockers, two groups of pharmaceuticals
that are used primarily in treatment of hypertension, might
inﬂuence DC function. ACE-inhibitors were shown to
suppress LPS-induced proinﬂammatory cytokine secretion
of moDCs [51] whereas calcium entry blockers prevent apo-
ptotic body engulfment by DCs and inhibit IL-12 secretion
[52, 53]. Yet, calcium entry blockers did not aﬀect the capa-
city of antigen-presenting cells to prime naive T cells or to
induce T helper-2 cell proliferation, nor the capacity of anti-
gen-presentation by DCs [54]. Hence, both classes of anti-
hypertensive drugs may suppress DC function, but are less
commonly used in the treatment of CAD patients.
If these in vitro studies on the eﬀects of cardiovascular
drugs on human moDCs and mouse bone-marrow-derived
DCs can be translated to CAD patients, they would aﬀect
blood DC numbers. As aspirin stimulates early diﬀerentia-
tion of CD11c+ DCs from bone marrow progenitors, aspirin
therapy might lead to increased circulating DC numbers
rather than decreased numbers. Furthermore, if statins inhi-
bit the adhesion and transmigration of DCs through activat-
ed endothelial cells, this would result in less recruitment of
DCs in atherosclerotic plaques, and thus retention of DCs in
thecirculation.Indeed,weshowedrecentlythatuseofstatins
was associated with increased numbers of mDCs whereas
pDC counts were unaﬀected [27]. Also DC activation is
to some extent inhibited by statins, aspirin, ACE-I, and
calcium entry blockers, which might explain their immature
phenotype in an inﬂammatory condition as atherosclerosis.
Finally, as beta blockers might reverse changes in leukocyte
distribution and have pleiotropic eﬀects on inﬂammatory
responses, the decline of circulating DCs in CAD may be less
pronounced in patients on a beta-blocker therapy as well.
In a recent study, we analyzed the eﬀect of medication by
including “control patients,” that is, patients with chest pain
a n ds u s p e c t e dC A D ,w h oa p p e a r e dt oh a v ec o r o n a r ya r t e r i e s
with less than 50% stenosis, instead of healthy volunteers
[27]. This control population did not signiﬁcantly diﬀer
from CAD patients with respect to the intake of medication.
Yet, patients with proven CAD had lower blood counts
of both subsets of DCs, strengthening the idea that their
decline in CAD is not a bystander eﬀect of cardiovascular-
related drugs. Yilmaz et al. came to the same conclusion
for statins, aspirin and beta blockers [28]. Moreover, in a
factorial analysis of variance lipid-lowering drugs and beta
blockers augmented, rather than decreased, the number
of circulating mDCs in CAD, without aﬀecting pDCs.
Aspirin, angiotensin-converting enzyme ACE/AII inhibitors
and calcium entry blockers had no impact on DC numbers
[27]. As this was only a limited pilot study, more studies are6 Mediators of Inﬂammation
required to investigate the impact of medication on circulat-
ing DC numbers and function.
2.3.7. Increased Recruitment of DCs from the Circulation to
Inﬂammatory Sites. An attractive explanation for decreased
circulating DC numbers might be increased recruitment of
DCs into the vessel wall or lymphoid organs. Indeed it has
been mentioned that DC numbers of lymph nodes attached
toatheroscleroticwallsegmentsexceedthoseinlymphnodes
attachedtononatheroscleroticarteries[7].Astothepresence
of DCs in healthy and diseased arteries, several studies have
been done and these are discussed in the second part of this
review.
3. DCs in Atherosclerotic Lesions
The presence of DCs in human arteries was ﬁrst described by
Bobryshev and Lord 1995 [55–57]. By electron microscopy
they demonstrated distinct morphologic characteristics that
allow unambiguous identiﬁcation of “vascular DCs” [7,
55, 58, 59]. In addition, DCs in human arteries were
identiﬁed using immunohistochemical staining for S100
(Figure 3(a))[ 56], langerin [60], CD1a [61], and fascin
(Figure 3(b))[ 62], which identify immature/mature subsets
ofDCs.Morerecenthistologicalstudiesaddedageneral(im-
mature and mature) DC marker: DC-SIGN [63, 64]a n d
mature DC markers, such as DC-LAMP [65], CD1a [58,
60], and CD83 [65–67]. Therefore, as suggested above, an
attractive explanation for the decline in blood DCs is active
recruitmentintoatheroscleroticlesions.Indeed,thepresence
ofbloodDCmarkersBDCA-1,BDCA-2[26, 68, 69], CD11c,
and CD123 [70–73] has been described in atherosclerotic
plaques. Nevertheless, as summarized in Table 1 and discuss-
ed below, there remains a lot of uncertainty on quality and
speciﬁcity of immunohistochemical DC markers.
3.1. Pitfalls When Examining DCs in Atherosclerotic Plaques.
At ﬁrst, it became clear that autolysis in autopsy specimens
and ﬁxation destroy or shield most cell surface(CD) epitopes
[69]. This means that nearly all DC markers cannot be
studied in formaldehyde-ﬁxed human autopsy specimens,
and therefore information on their presence in early plaque
stages is lacking. For these surface markers (e.g., CD83, and
BDCA-1, BDCA-2) only freshly frozen, unﬁxed endarterec-
tomy specimens yield reliable results [69].
Secondly, false-positive results, resulting from unspeciﬁc
binding of antibodies to plaque components often occur in
atherosclerotic plaques [82]. The oxidative processes in
advanced plaques lead to creation of hot spots of multiple
neoantigens, and these may bind primary or secondary
antibodies, particularly if used in inappropriate dilutions.
Therefore, optimized immunohistochemistry protocols are
an absolute prerequisite. For instance CD83 [63, 67, 69]a n d
BDCA antigens [69] could be detected in human plaques
[69], but they were less eminently present than reported by
others [26, 65, 83]. Actually we suspect that in some studies
the primary antibody against those epitopes was far too
concentrated, and even combined with signal ampliﬁcation
methods that will increase background staining even further.
Thirdly the lack of DC speciﬁc markers makes identiﬁca-
tion of vascular DCs by means of immunohistochemistry far
more diﬃcult than with ﬂow cytometry in which a panel
of markers enables unequivocal positive or negative (for
other lineages) detection of various cell types. For instance,
the markers CD11c and CD123, which have been used to
detect blood DCs in plaques [70, 84], are also expressed by,
respectively, monocytes/macrophages and endothelial cells
[69]. Fascin is most frequently used to detect vascular DCs
[62, 65, 66, 68, 73–76], but we recently showed abundant
fascinexpressioninendothelialcellsandneovesselsinplaque
shoulders and in complicated lesions [69, 77] (Figure 3(c)).
Also the lipid antigen presenting molecule, CD1a appeared
to be unspeciﬁc for plaque DCs as it identiﬁed also foam
cells, CD14+ monocytes, and CD68+ macrophages [69, 81],
whereas the activation marker CD83 can be present on T-
cells or activated monocytes and macrophages in advanced
plaques [69, 85, 86]. Though double immunoﬂuorescence
staining can be used to check multiple markers on indi-
vidual cells, the very high levels of autoﬂuorescence in
atherosclerotic plaques make routine application of this
technique impossible. At the moment we propose S100 as
the most reliable and general marker of DCs in plaques
DCs (Figure 3(a)), but not in the adventitia where it stains
nerve twigs. Fascin may yield reliable results (Figure 3(b)),
but only in early lesions that are still devoid of intraplaque
angiogenesis.
Finally, there is no universal DC marker that is expressed
by all DCs. Indeed, few DCs simultaneously expressed
the most reliable markers fascin and S100 [69], and the
presence of DCs as detected by immunohistochemistry is
markedly lower than DC numbers identiﬁed by electron-
microscopy [55, 58]. Therefore, one has to keep in mind that
quantiﬁcation of intimal DCs by one marker will only give
information on a particular DC subtype.
3.2. Diﬀerent DC Subtypes in Atherosclerotic Lesions
3.2.1. DC Precursors in Advanced Atherosclerotic Plaques.
Interestingly, both mDC and pDC precursor markers were
found in carotid atherosclerotic plaques, although less
BDCA-2+ (pDC marker) cells were present [69]. Yilmaz et
al. described comparable results in atherosclerotic coronary
arteries [26]. These ﬁndings are substantiated by the fact that
gene expression analysis for pathogen-sensing Toll-like re-
ceptors (TLRs) 1 to 9 showed vessel-speciﬁc proﬁles, with
the mDC receptors TLR2 and TLR4 ubiquitously present,
but the pDC receptors TLR7 and TLR9 infrequently so [87].
Niessner et al. described the presence of plaque residing
CD123+ pDCs in advanced plaques, suggesting that they can
amplify cytolytic T-cell functions and may thus connect host
infection and plaque instability [70].
The demonstration of BDCA-2+ and BDCA-1+ cells
in human plaques strongly suggests that blood DCs are
recruit-ed into advanced lesions. This is further strength-
ened by the observation that both BDCA+ subsets wereMediators of Inﬂammation 7
Table 1: Immunohistochemical markers to identify DCs in human plaques.
Marker DC type References Pitfalls References
Fascin (p55) Immature/mature DCs; DC
speciﬁc in early plaque stages
[7, 59, 62,
65, 66, 68,
69, 73–77]
Capillary ECs, migrating
vascular cells in plaque shoulders
and advanced plaques
[69, 77]
S100 (S100B and weakly S100A1)
Immature/mature DCs; DC
speciﬁc in normal intima and all
plaque stages
[7, 7, 56,
59, 61, 65,
68, 69, 77–
79]
Nerve bundles and twigs in
adventitia [7, 56, 59, 69]
Langerin
Selectively expressed on the
surface and in Birbeck granules
of Langerhans cells
[60, 69]V e r y f e w c e l l s [ 60, 69]
CD1a Mature DCs [67, 74, 78,
80] CD14+,C D 6 8 + foam cells [69, 81]
CD83 Mature DCs [65–67]
Aspeciﬁc staining due to signal
ampliﬁcation? Activated T cells
and monocytes?
[63, 69]
DC-SIGN (CD209) Immature/mature DCs [63, 64] Macrophages [63]
DC-LAMP (CD208) Mature DCs [65]
BDCA-1 (CD1c) mDC [26, 68,
69] Bc e l l s [ 23]
BDCA-2 (CD303) pDC precursor [26, 68,
69] [23, 38]
CD11c mDCs [71–73] CD14+ monocytes and CD68+
macrophages [69]
CD123 pDCs [70–73] ECs, microvessels in advanced
plaques, and plaque shoulders [69]
DC: dendritic cells, EC: endothelial cell, pDC: plasmacytoid DC, mDC: myeloid DC.
S100
Lumen
(a)
Fascin
(b)
Fascin
(c)
BDCA-1
∗
(d)
BDCA-2
∗
(e)
Figure 3: Examples of useful plaque DC markers: S100 (a), fascin (b, c), BDCA-1 (d) and BDCA-2 (e). Arrows indicate DCs. Arrowheads
show fascin+ neovessels. ∗ indicates lumen of microvessel.8 Mediators of Inﬂammation
Increased recruitment of
b l o o dD Cp r e c u r s o r s
Increased diﬀerentiation
from intimal CD34+ cells,
monocytes, macrophages
Increased cell proliferation or
increased survival/cell death of intimal DCs
Decreased eﬄux from
plaques
Origin of vascular
DCs?
DC function and
traﬃcking in
atherosclerosis?
Mechanisms of DC
recruitment? I
II
III
IV
Possible mechanisms Remaining questions
Increase of
intimal DCs
with
atherosclerotic
plaque stage
Figure 4: Possible mechanisms responsible for the increase of vascular DCs in atherosclerosis.
predominantly found around microvessels [69]. At the
moment there still is a lack of information on their
potential presence in early atherosclerotic lesions, due to
the fact that their markers cannot be investigated in ﬁxed
arteries.
3.2.2. Immature/Mature DCs in Atherosclerotic Plaques.
S100+ and fascin+ DCs are found in normal arteries and in
all successive stages of atherosclerotic lesions [7, 59, 65, 69].
Interestingly, atheroprone regions (subjected to hemodyna-
micstress)containmoreDCsthanatheroresistantareas[88].
Small numbers of DCs are located along the endothelium in
the subendothelial layer of the intima of apparently normal,
nondiseased arteries, even in children [78, 89]. Wick et al.
proposed that these intimal DCs are part of a “vascular as-
sociated lymphoid tissue” (VALT), which also consists of T
cells and macrophages, and screens the vessel wall for poten-
tially harmful antigens [32, 90, 91].
Though the presence of S100 in normal intimal thicken-
ings is limited, numbers of S100+ cells increase successively
from intimal thickening, via pathological intimal thickening,
ﬁbrous cap atheroma and ﬁnally complicated plaques [56,
69]. Fascin+ cells follow the same pattern, but are more
abundant [26, 69, 76, 83]. For early plaque stages this is a
real ﬁnd zing, but in lesions containing microvessels (plaque
shoulders, complicated plaques, and most endarterectomy
specimens) this was partly ex-plained by staining of fascin-
positive endothelial cells [69].
3.2.3. Mature, Antigen-Presenting DCs in Atherogenic Lesions.
The report on abundant presence of CD83+ cells in plaque
shoulders [65] is often cited as evidence that atherosclerotic
plaques contain many activated DCs. However the markers
CD1a and CD83 are technically diﬃcult or less speciﬁc for
detection of mature DCs. Therefore, it is in our view still
debatable whether mature DC counts augment when plaque
stages increase. Nevertheless, mature DCs can be found in
advanced lesions, and it became clear that DCs form close
interactions with T cells in advanced atherosclerotic lesions,
suggestingthatinsituT-cellactivationdoesoccur[65,67,69,
74].
3.3. Possible Mechanisms for Increased DCs in Atherosclerotic
Arteries. Diﬀerent explanations for increased DC numbers
in atherosclerotic lesions are discussed below and summari-
zed in Figure 4.
3.3.1. Increased Inﬂux of Blood DC Precursors. At ﬁrst and
in view of the many reports on diminished blood DCs in
patients with established atherosclerosis, one likely explana-
tion is increased invasion of DC precursors from the blood
into the arterial lesions. This hypothesis is strengthened by
the present markers of pDCs and mDCs around neovessels.
Future studies will have to determine whether a link exists
not only between plaque type and numbers of lesional DCs,
but also with blood DC counts. It is possible that, the clinical
division in stable or unstable, was not reﬁned enough to
detect this correlation. Ideally, DCs have to be investigated
in peripheral blood and plaque samples of the same patient,
or in an animal model of experimental atherosclerosis, with
ﬂuorescence labeling of DCs, to characterize their origin,
to postulate an increased inﬂux of blood DC precursors as
a mechanism for increased DC numbers in atherosclerotic
plaques. Direct information on the stimuli regulating DC
migration is scarce. However, it is known that eﬀective
mDC as well as pDC chemokine factors (CCL2, CCL5, and
CXCL-12) are elevated in patients with atherosclerosis [20–
22, 92]. In addition, endothelial cell adhesion molecules
such as E-selectin, P-selectin, and vascular cell adhesion
molecule-1 are increased in atherosclerosis and can enhance
invasion of monocytes or DC precursors [68]. Indeed,
endothelium activated in vitro by atherogenic factors such as
oxLDL orTNFalphaincreases moDCadhesion andendothe-
lial transmigration [93]. Furthermore, we recently showed
that endothelial cell dysfunction in humans (measured by
brachial vasodilatation in response to reactive hyperaemia)
does have an impact on the number of circulating mDCs.
Poor vasodilatation increased mDCs (but not pDCs) in the
blood, on top of the reduction evoked by CAD [27]. Finally,
experimental studies in mice suggest that DCs invade the
plaque via the arterial lumen [94] while the proliferation rate
of DCs in plaques is very low [95]. Interestingly, deﬁciency in
CX3CR1—a receptor of the chemokine fractalkine—in miceMediators of Inﬂammation 9
impaired the accumulation of DCs in the aortic wall and this
markedly reduced the atherosclerotic burden [96].
3.3.2. Increased Diﬀerentiation from Intimal CD34+ Cells
or Monocytes. In spite of these indications that blood DC
precursors might account for increased plaque DC numbers,
the origin of immature/mature (S100+ or fascin+)D C sr e -
mains unclear [7]. Until now it has not been shown that
DC precursors can give rise to plaque DCs [38]. Therefore, a
second and third explanation for the augmented presence of
DCs in atherosclerotic plaques are increased diﬀerentiation
of DCs from local vascular CD34+ stem cells [59]o rf r o m
inﬁltrated monocytes [38, 59, 95, 97]. Interestingly, aortic
lesions of GM-CSF-deﬁcient low-density lipoprotein recep-
tor null mice had a dramatic 60% decrease in CD11c+
DCs, suggesting that GM-CSF might be an important local
factor that determines DC numbers in the plaques [98].
In addition, several studies already pointed to the fact that
atherogenic factors such as oxLDL, phospholipase A2 type
IIA, and CRP could interfere with DC diﬀerentiation from
monocytes [99–101]. Moreover, next to monocytes also
macrophages and foam cells can turn into DCs [99, 102]. As
discussed below, this transition might be necessary to enable
migration to lymph nodes and plaque regression [103, 104].
3.3.3. Defective Emigration of DCs from Plaque to Lymphoid
Organs. It was recently suggested that the accumulation of
DCs in plaques could be the result of defective emigration
of DCs from the lesions to draining lymph nodes [38,
105]. In a mouse model of dyslipidemia it was shown
that altered serum lipids associated with atherosclerosis
changed DC activation and migration [106]. Further evi-
dence was given by transplantation of atherosclerotic seg-
ments from hypercholesterolemic ApoE−/− mice into wild-
type normocholesterolemic recipient mice. This resulted
in lesion regression whereas lesion development continued
progressively aftertransplantation into hypercholesterolemic
mice [104, 107, 108]. The rapid loss of plaque volume
aftertransplantationofsegmentsintonormocholesterolemic
mice, was explained by emigration of DCs to lymph nodes
[104, 109], while DC exit from aortic lesions was impaired in
hypercholesterolemic mice [104]. Troganet al. demonstrated
that CCR7 was increased after transplantation of the plaques
in normolipidemic mice [103]. In contrast, when CCR7
function was abrogated in vivo by treatment with antibodies
to CCR7 ligands CCL19 and CCL21, lesion size and foam
cell content did not regress [103]. Doherty et al. explained
that—in accordance with giant cell arteritis [110]—trapped
intimal DCs may not only trigger local inﬂammation, but it
may also lead to loss of local tolerance [105]. Nevertheless,
in human atherosclerotic arteries DCs can be regularly
observed traﬃcking through the media and the internal
elastic lamina [69, 74], but it is not known whether the rate
of cell ﬂuxes has changed.
4. GeneralConclusion
This review summarizes the current understanding of
the possible role of DCs in the pathogenesis of human
atherosclerosis. Concerning the early stages of DC dif-
ferentiation, that is, circulating DC precursors, it is now
unambiguous that they are signiﬁcantly decreased in CAD
patients, irres-pective of the blood DC markers used for
enumeration.Exactmechanismsresponsiblefortheirdecline
remain unclear. However, there are indications pointing to
impaired diﬀerentiation from bone marrow progenitors, and
to activation and subsequent recruitment to inﬂammatory
sites,suchasatheroscleroticplaques.Indeed,bothmDCsand
pDCs can be found in human plaques, particularly around
neovessels in areas with angiogenesis. Furthermore, DC
counts in the intima of arteries increase with evolving plaque
stages, and activated DCs are seen in close relationship with
lesional T cells. To which extent these interactions between
DCs and T cells result in progression or dampening of
atherosclerosis is, however, not yet clear. Interestingly, it has
been demonstrated in mice that decreased accumulation of
DCs in the arterial intima can lead to attenuated plaque
progression [96] .H o w e v e r ,ap r o t e c t i v er o l ef o rD C si n
atherosclerosis by regulating cholesterol homeostasis [111]
has also been shown. Furthermore, increasing evidence
points to diﬀerent behaviour of mDCs and pDCs in
atherosclerosis. The mDCs from CAD patients and controls
responded similar to ex vivo stimulation, while pDCs
from CAD patients were subactive. To elucidate possible
atheropromoting or protective functions of blood DCs
in humans, studies investigating the relationships between
plaque composition, size, and stability by means of IVUS,
and numbers and functional status of circulating pDCs and
mDCs would be helpful. However, in the end experimental
studies in animal models of atherosclerosis are required to
unravel DC function, life cycle, activation, and traﬃcking
in atherosclerosis. As DCs recognize atherosclerosis-related
antigens and are renowned as potent immune-regulatory
cells, they may possibly be manipulated and deployed in the
future in order to delay the atherosclerotic disease process in
humans.
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